Journal of Hepatology
Volume 54, Issue 1 , Pages 56-63, January 2011

Bleeding in patients with Budd–Chiari syndrome

  • Pierre-Emmanuel Rautou

      Affiliations

    • Pôle des Maladies de l’Appareil Digestif, Service d’Hépatologie, Hôpital Beaujon, AP-HP, Clichy, France
    • INSERM, U773, Centre de Recherche Biomédicale Bichat Beaujon CRB3, Université Paris 7-Denis-Diderot, Clichy, France
    • These authors contributed equally to this work.
  • ,
  • Ludivine Douarin

      Affiliations

    • Pôle des Maladies de l’Appareil Digestif, Service d’Hépatologie, Hôpital Beaujon, AP-HP, Clichy, France
    • INSERM, U773, Centre de Recherche Biomédicale Bichat Beaujon CRB3, Université Paris 7-Denis-Diderot, Clichy, France
    • These authors contributed equally to this work.
  • ,
  • Marie-Hélène Denninger

      Affiliations

    • Service d’Hématologie Biologique, Hôpital Beaujon, Clichy, France
  • ,
  • Sylvie Escolano

      Affiliations

    • INSERM U780, IFR69, 16 Avenue Paul Vaillant Couturier 94807 Villejuif, France
  • ,
  • Didier Lebrec

      Affiliations

    • Pôle des Maladies de l’Appareil Digestif, Service d’Hépatologie, Hôpital Beaujon, AP-HP, Clichy, France
    • INSERM, U773, Centre de Recherche Biomédicale Bichat Beaujon CRB3, Université Paris 7-Denis-Diderot, Clichy, France
  • ,
  • Richard Moreau

      Affiliations

    • Pôle des Maladies de l’Appareil Digestif, Service d’Hépatologie, Hôpital Beaujon, AP-HP, Clichy, France
    • INSERM, U773, Centre de Recherche Biomédicale Bichat Beaujon CRB3, Université Paris 7-Denis-Diderot, Clichy, France
  • ,
  • Michel Vidaud

      Affiliations

    • Laboratoire de Biochimie, Hôpital Beaujon, Clichy, France
  • ,
  • Raphaël Itzykson

      Affiliations

    • Service d’Hématologie Clinique, Hôpital Avicenne, AP-HP, Université Paris 13, Bobigny, France
  • ,
  • Rami Moucari

      Affiliations

    • Pôle des Maladies de l’Appareil Digestif, Service d’Hépatologie, Hôpital Beaujon, AP-HP, Clichy, France
    • INSERM, U773, Centre de Recherche Biomédicale Bichat Beaujon CRB3, Université Paris 7-Denis-Diderot, Clichy, France
  • ,
  • Annie Bezeaud

      Affiliations

    • Service d’Hématologie Biologique, Hôpital Beaujon, Clichy, France
  • ,
  • Dominique Valla

      Affiliations

    • Pôle des Maladies de l’Appareil Digestif, Service d’Hépatologie, Hôpital Beaujon, AP-HP, Clichy, France
    • INSERM, U773, Centre de Recherche Biomédicale Bichat Beaujon CRB3, Université Paris 7-Denis-Diderot, Clichy, France
    • Corresponding Author InformationCorresponding author at: Service d’Hépatologie and INSERM CRB3, Hôpital Beaujon, AP-HP, Clichy, France. Tel.: +33 1 40 87 55 94; fax: +33 1 40 87 44 26.
  • ,
  • Aurélie Plessier

      Affiliations

    • Pôle des Maladies de l’Appareil Digestif, Service d’Hépatologie, Hôpital Beaujon, AP-HP, Clichy, France
    • INSERM, U773, Centre de Recherche Biomédicale Bichat Beaujon CRB3, Université Paris 7-Denis-Diderot, Clichy, France

Received 30 December 2009; received in revised form 10 May 2010; accepted 8 June 2010. published online 31 August 2010.

Background & Aims

Anticoagulation therapy is recommended for patients with Budd–Chiari syndrome (BCS). This study aimed to assess the incidence, severity, and risk factors of major bleeding in patients with Budd–Chiari syndrome (BCS) receiving anticoagulation therapy.

Methods

We evaluated 94 consecutive BCS patients. Major bleeding required hospitalization, and/or transfusion of ⩾2 red blood cell units, and/or was located intracranially, and/or retroperitoneally, and/or was fatal.

Results

After a median follow-up of 43months, 47 patients had 92 major bleeding episodes (22.8 per 100 patient-years). Forty episodes were related to invasive therapy for BCS. The origin of the 52 other episodes was gastrointestinal in 26 (including 15 related to portal hypertension) and genital in 10; 26 were spontaneous and 26 provoked. Excess anticoagulation was identified in 13 (27%) out of 49 documented episodes. Bleeding was managed by interrupting or reducing anticoagulation in 34 episodes, surgery in 18, endoscopy in 12, and radiological intervention in 8. The presence of esophageal varices was an independent predictor of bleeding unrelated to invasive therapy for BCS. Bleeding contributed to death in five patients and caused neurological complications in two. These poor outcomes were associated with more severe liver disease at baseline.

Conclusions

Major bleeding is common in BCS patients receiving anticoagulation therapy. Invasive procedures and portal hypertension are major factors, while excess anticoagulation plays a secondary role. Baseline BCS severity is the main determinant of prognosis at bleeding. Reducing anticoagulation intensity during invasive therapy and reinforced prophylaxis for portal hypertension could improve the benefit-risk ratio of anticoagulation.

Abbreviations: BCS, Budd–Chiari syndrome, INR, International Normalized Ratio, LMWH, Low-molecular-weight heparin, TIPS, transjugular intrahepatic portosystemic shunting, VTE, venous thromboembolism

Keywords: Hemorrhage, Portal hypertension, Hepatic venous outflow, Anticoagulation, Heparin, Bleeding, Gastroesophageal varices

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0168-8278(10)00709-9

doi:10.1016/j.jhep.2010.06.019

Journal of Hepatology
Volume 54, Issue 1 , Pages 56-63, January 2011